CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack.
about
Role of immune escape mechanisms in Hodgkin's lymphoma development and progression: a whole new world with therapeutic implicationsEmerging drugs for chronic lymphocytic leukaemia.Comparative analysis of MVA-CD40L and MVA-TRICOM vectors for enhancing the immunogenicity of chronic lymphocytic leukemia (CLL) cells.EBV-gp350 confers B-cell tropism to tailored exosomes and is a neo-antigen in normal and malignant B cells--a new option for the treatment of B-CLLExploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia.Lycorine sensitizes CD40 ligand-protected chronic lymphocytic leukemia cells to bezafibrate- and medroxyprogesterone acetate-induced apoptosis but dasatanib does not overcome reported CD40-mediated drug resistance.Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphomaChronic lymphocytic leukemia patients have a preserved cytomegalovirus-specific antibody response despite progressive hypogammaglobulinemiaUpregulation of bfl-1 is a potential mechanism of chemoresistance in B-cell chronic lymphocytic leukaemia.The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cellsVinblastine rapidly induces NOXA and acutely sensitizes primary chronic lymphocytic leukemia cells to ABT-737.Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progressionInvestigational immunotherapeutics for B-cell malignancies.Tuning of CD40-CD154 interactions in human B-lymphocyte activation: a broad array of in vitro models for a complex in vivo situation.Treatment of chronic lymphocytic leukemia requires targeting of the protective lymph node environment with novel therapeutic approaches.BCL2A1: the underdog in the BCL2 family.ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia.The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53.Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis.CD40 stimulation sensitizes CLL cells to rituximab-induced cell death.CLL cells are resistant to smac mimetics because of an inability to form a ripoptosome complex.Selective IAP inhibition results in sensitization of unstimulated but not CD40-stimulated chronic lymphocytic leukaemia cells to TRAIL-induced apoptosis.The impact of SF3B1 mutations in CLL on the DNA-damage response.Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation.Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia.Two distinct molecular subtypes of chronic lymphocytic leukemia give new insights on the pathogenesis of the disease and identify novel therapeutic targets
P2860
Q27011510-4E36881E-EFA2-40E3-9C2F-F291ECF7679CQ30353154-1B9D93B4-5006-48C8-BCA1-F5112796291CQ33938820-21E7B3D1-0525-4CA8-A231-A6A2B102F815Q34055555-9A1EB344-9C26-4032-97C3-68F0633F09EEQ34056568-23899C81-C289-4CE9-A785-83876E48D392Q34255124-55210338-3F5F-4D19-9863-5A300DB7904DQ34448586-C1D71309-D264-4F9D-8C28-80679CA46534Q35032658-4C7FCF96-61C0-4370-BB28-93265D33B4FEQ36611156-7F8B133C-B8CD-4E36-ABDF-D1D13BC19E90Q36787532-E1F28B1A-7F27-4273-8050-D7C8CC52FBEEQ37092954-BDC9186A-EE22-48AF-BB3D-B932152DA138Q37439573-87C189D1-C1B5-4204-8EB6-A7FCFE95C826Q37667386-8B8AB23D-2885-4C9C-BD8E-830D05CDC559Q37828473-F246930C-799C-44C1-B840-5F61C2AE13C6Q37910914-93C143F6-4EE9-4A32-A360-16790A51D579Q37954995-88893088-DAB2-452D-9629-878C4E95F576Q38891225-D767B571-72B2-407E-88E0-4B3909834D8DQ40575812-F17B05F5-B3F4-47E7-8D66-7B5DE19D7BF1Q41953887-176F4CE0-85B9-48D0-BBAC-C9EB009E7FAEQ42089513-1BA4B39D-ECAD-4AE6-9E82-9C6A81919D07Q42485265-09702880-C354-4CB8-A8C3-F5A38B63801CQ42585598-C737E6F3-2291-4D89-984A-C608879F79CCQ42930877-36F100CD-9C63-4286-962B-45BC36151614Q44290485-5F716F20-D69F-4CFC-A43A-CE09FDA44E99Q45240553-33D1E1A4-418F-40DD-AF2A-7B4366698AB4Q47771952-1CF9FD5E-52CC-4FF5-B380-8B409C357110Q58010698-55F30E44-7871-42A5-B9D1-20A50DBB207D
P2860
CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
CD40 stimulation of B-cell chr ...... cytotoxic T-lymphocyte attack.
@en
CD40 stimulation of B-cell chr ...... cytotoxic T-lymphocyte attack.
@nl
type
label
CD40 stimulation of B-cell chr ...... cytotoxic T-lymphocyte attack.
@en
CD40 stimulation of B-cell chr ...... cytotoxic T-lymphocyte attack.
@nl
prefLabel
CD40 stimulation of B-cell chr ...... cytotoxic T-lymphocyte attack.
@en
CD40 stimulation of B-cell chr ...... cytotoxic T-lymphocyte attack.
@nl
P2093
P2860
P921
P1476
CD40 stimulation of B-cell chr ...... cytotoxic T-lymphocyte attack
@en
P2093
Annelieke Jaspers
Arnon P Kater
Eric Eldering
Ludo M Evers
Marinus H J van Oers
Michiel F Oosterwijk
P2860
P304
P356
10.1111/J.1365-2141.2004.05225.X
P407
P577
2004-11-01T00:00:00Z